PHAT · NASDAQ
Phathom Pharmaceuticals (PHAT) Stock Price & Fundamentals
Phathom Pharmaceuticals (PHAT) closed at $479.89 on Oct 9, 2026, up 0.79% from the previous close of $476.12.
Share price, past year
1Y +0.42%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $479.89 |
| Sep 30, 2026 | $464.31 |
| Aug 31, 2026 | $466.74 |
| Jul 31, 2026 | $495.86 |
| Jun 30, 2026 | $519.23 |
| May 29, 2026 | $539.10 |
| Apr 30, 2026 | $499.59 |
| Mar 31, 2026 | $493.17 |
| Feb 27, 2026 | $514.84 |
| Jan 30, 2026 | $518.97 |
| Dec 31, 2025 | $478.50 |
| Nov 28, 2025 | $499.06 |
| Oct 31, 2025 | $482.64 |
Key statistics
- Market cap
- $38.42B
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- $239.66M
- Net income (TTM)
- −$99.07M
- Shares outstanding
- 80.1M
- Dividend yield
- —
- 52-week range
- $450.75 – $545.08
Phathom Pharmaceuticals's market cap is $38.42B, based on a share price of $479.89 and 80.1M shares outstanding as of Jun 30, 2026.
Financials
Phathom Pharmaceuticals reported revenue of $175.11M for fiscal 2025, up 216.93% from fiscal 2024.
Phathom Pharmaceuticals reported a net loss of $221.25M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $175.11M | +216.9% | −$221.25M | −126.4% | −$3.03 | −$167.00M |
| FY2024ended Dec 31, 2024 | $55.25M | +8,001.5% | −$334.33M | −605.1% | −$5.29 | −$266.91M |
| FY2023ended Dec 31, 2023 | $682.00K | — | −$201.59M | −29,558.9% | −$3.93 | −$139.21M |
| FY2022ended Dec 31, 2022 | $0.00 | — | −$197.72M | — | −$5.05 | −$147.57M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $74.27M | −$17.58M | −$0.21 |
| Q1 FY2026ended Mar 31, 2026 | $58.30M | −$30.37M | −$0.37 |
| Q4 FY2025ended Dec 31, 2025 | $57.58M | −$21.15M | — |
| Q3 FY2025ended Sep 30, 2025 | $49.50M | −$29.97M | −$0.41 |
| Q2 FY2025ended Jun 30, 2025 | $39.50M | −$75.81M | −$1.05 |
| Q1 FY2025ended Mar 31, 2025 | $28.52M | −$94.32M | −$1.31 |
| Q4 FY2024ended Dec 31, 2024 | $29.66M | −$74.45M | — |
| Q3 FY2024ended Sep 30, 2024 | $16.35M | −$85.58M | −$1.32 |
Company profile
- Name
- Phathom Pharmaceuticals, Inc.
- Ticker
- PHAT
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 100 Campus Drive,, Suite 102, Florham Park, NJ 07932
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001783183
Recent SEC filings
- Sep 29, 2026
- Jul 30, 2026
- Jul 30, 2026
- Jun 23, 2026
- May 21, 2026
- Apr 30, 2026
- Apr 30, 2026
- Feb 26, 2026
Frequently asked questions
What is Phathom Pharmaceuticals's stock price?
Phathom Pharmaceuticals (PHAT) closed at $479.89 on Oct 9, 2026, up 0.79% from the previous close of $476.12.
What is Phathom Pharmaceuticals's market cap?
Phathom Pharmaceuticals's market cap is $38.42B, based on a share price of $479.89 and 80.1M shares outstanding as of Jun 30, 2026.
How much revenue does Phathom Pharmaceuticals make?
Phathom Pharmaceuticals reported revenue of $175.11M for fiscal 2025, up 216.93% from fiscal 2024.
Does Phathom Pharmaceuticals pay a dividend?
Phathom Pharmaceuticals's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Phathom Pharmaceuticals, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures